Replies to post #115618 on Amarin Corp Plc (AMRN)

[jessellivermore]

1wfal...

Quote: "I think it likely it has some interesting benefit somewhere, but probably not enough on the primary endpoint (or has enough side effects to cause it not to be worthwhile.)."

You still don't get it...Its not the RRR and the P value of the PE...Its about the number of events in the data points..We already know the RRR is going to be fine...Worse case it's over 20%...

You remind me of a saying from one of my old bosses Aurthur Kantrowitz the head of AVCO Everette Research labs..."The rest is just engineering."...Ie. trivial.

":>) JL

[IslandOfMisfitToys]

That said, of course I think the trial has a LOT of risk. In a way very similar to ONTY

I don't disagree. I really like the inflammation theory here, but it's a theory.

The thing I like better here is that this is not an oncology play.

I have had it with chasing oncology plays!